Hyaline-Vascular Type Castleman’s Disease, Sarcoidosis, and Crohns Disease
Tóm tắt
Sarcoidosis and Crohns disease have been associated with increased long term risk of lymphoproliferative disorders, including lymphomas. Newly developed lymphadenopathy in a patient with these disorders should prompt pathological evaluation. Castleman’s disease is a lymphoproliferative disorder characterized by enlarged hyperplastic lymph nodes with regressed follicles surrounded by expanded mantle zones of small lymphocytes, and interfollicular vascular proliferation in the hyaline-vascular type. Similar to sarcoidosis and Crohns disease, its etiology is incompletely understood, although immune dysregulation, genetic factors and infectious and environmental factors are thought to play a role in all three diseases. Interleukin-6 is a possible pathological common factor between these three disease processed. Unicentric, hyaline-vascular type Castleman’s disease can be treated successfully with complete surgical resection. We report a patient with long history of sarcoidosis and Crohns disease with newly developed lymphadenopathy which was found to be due to Castleman’s disease.
Tài liệu tham khảo
Herrada J, Cabanillas F, Rice L, Manning J, Pugh W (1998) The clinical behavior of localized and multicentric Castleman disease. Ann Intern Med 128(8):657–662
Castleman B, Iverson L, Menendez VP (1956) Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer 9(4):822–830
Iannuzzi MC, Rybicki BA, Teirstein AS (2007) Sarcoidosis. N Engl J Med 357(21):2153–2165
Awano N, Inomata M, Kondoh K et al (2012) Mixed-type multicentric Castleman’s disease developing during a 17-year follow-up of sarcoidosis. Intern Med 51(21):3061–3066
Rice BL, Farver CF, Pohlman B, Burkey BB, Parambil JG (2011) Concomitant Castleman’s disease and sarcoidosis. Am J Med Sci 341(3):257–259
Burak KW, Bridges RJ, Blahey WB (1998) Castleman’s disease and neutropenic enterocolitis presenting as Crohn’s disease. Canadian journal of gastroenterology. Journal canadien de gastroenterologie 12(4):270–272
Yavasoglu I, Kadikoylu G, Meteoglu I, Bolaman Z (2009) Hyaline-vascular type of Castelman’s disease associated with Crohn’s disease. Int J Colorectal Dis 24(1):123–124
Thoufeeq MH, Perry MJ (2007) Castleman’s disease in a patient with celiac disease. Indian J Gastroenterol 26(4):187
Browne D, Barton EN, Barrow KO, Williams NP, Hanchard B (1996) Multicentric angiofollicular lymph node hyperplasia in ulcerative colitis. A case report. West Indian Med J 45(1):34–36
Girgis RE, Basha MA, Maliarik M, Popovich J Jr, Iannuzzi MC (1995) Cytokines in the bronchoalveolar lavage fluid of patients with active pulmonary sarcoidosis. Am J Respir Crit Care Med 152(1):71–75
Nishimoto N (2005) Clinical studies in patients with Castleman’s disease, Crohn’s disease, and rheumatoid arthritis in Japan. Clin Rev Allergy Immunol 28(3):221–230
Yoshizaki K, Matsuda T, Nishimoto N et al (1989) Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman’s disease. Blood 74(4):1360–1367
Nishimoto N, Kanakura Y, Aozasa K et al (2005) Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 106(8):2627–2632
van Rhee F, Wong RS, Munshi N et al (2014) Siltuximab for multicentric Castleman’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol 15(9):966–974
Talat N, Belgaumkar AP, Schulte KM (2012) Surgery in Castleman’s disease: a systematic review of 404 published cases. Ann Surg 255(4):677–684
Askling J, Brandt L, Lapidus A et al (2005) Risk of haematopoietic cancer in patients with inflammatory bowel disease. Gut 54(5):617–622
Askling J, Grunewald J, Eklund A, Hillerdal G, Ekbom A (1999) Increased risk for cancer following sarcoidosis. Am J Respir Crit Care Med 160(5 Pt 1):1668–1672
Papanikolaou IC, Sharma OP (2010) The relationship between sarcoidosis and lymphoma. Eur Respir J 36(5):1207–1209
Keller AR, Hochholzer L, Castleman B (1972) Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer 29(3):670–683
Shahidi H, Myers JL, Kvale PA (1995) Castleman’s disease. Mayo Clin Proc 70(10):969–977
Dispenzieri A, Gertz MA (2005) Treatment of Castleman’s disease. Curr Treat Options Oncol 6(3):255–266